PMC:4693303 / 26962-27858 JSONTXT

Annnotations TAB JSON ListView MergeView

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4693303","sourcedb":"PMC","sourceid":"4693303","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4693303","text":"The presence of EBOV disease was sought during the first 10 days after vaccination. There were no cases of Ebola in the immediate vaccine group, and in the delayed group there were 16 cases from seven clusters. In brief, the vaccine demonstrated excellent overall efficacy.[62] However, there were few cases in the immediate vaccine group beyond the 10-day window and because the groups were small, the true efficacy will likely be somewhere between 75% and 100%.[63] Regardless, these results are exceptionally promising. Of note, it has been proposed that the development of vaccine should focus on more than one route of delivery, highlighting the possibility of creating and implementing nasal immunization that would provide a number of distinct benefits, including ease of delivery, improved patient compliance, and application of such methodology to other emerging infectious diseases.[64]","tracks":[{"project":"TEST0","denotations":[{"id":"26752867-234-240-1465731","span":{"begin":274,"end":276},"obj":"[\"26248676\"]"},{"id":"26752867-230-236-1465732","span":{"begin":893,"end":895},"obj":"[\"25796987\"]"}],"attributes":[{"subj":"26752867-234-240-1465731","pred":"source","obj":"TEST0"},{"subj":"26752867-230-236-1465732","pred":"source","obj":"TEST0"}]},{"project":"2_test","denotations":[{"id":"26752867-26248676-60482797","span":{"begin":274,"end":276},"obj":"26248676"},{"id":"26752867-25796987-60482798","span":{"begin":893,"end":895},"obj":"25796987"}],"attributes":[{"subj":"26752867-26248676-60482797","pred":"source","obj":"2_test"},{"subj":"26752867-25796987-60482798","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"TEST0","color":"#9593ec","default":true},{"id":"2_test","color":"#aaec93"}]}]}}